Diferencia entre revisiones de «Misoprostol»
(Text replacement - "Category:Drugs" to "Category:Pharmacology") |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (No se muestran 2 ediciones intermedias de 2 usuarios) | |||
| Línea 1: | Línea 1: | ||
==General== | ==General== | ||
*Type: | *Type: Prostaglandin | ||
*Dosage Forms: | *Dosage Forms: | ||
*Routes of Administration: | *Routes of Administration: | ||
| Línea 14: | Línea 14: | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: X | ||
*[[Lactation risk categories|Lactation risk]]: | *[[Lactation risk categories|Lactation risk]]: Excreted in breastmilk | ||
*Renal Dosing | *Renal Dosing: not defined | ||
*Hepatic Dosing: not defined | |||
*Hepatic Dosing | |||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*Pregnancy (when used to treat ulcers) | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Anaphylaxis | |||
*Dysrhythmia, MI | |||
*GI bleed | |||
*Uterine rupture | |||
*Thromboembolic disorder | |||
===Common=== | ===Common=== | ||
*Diarrhea, abdominal pain, flatulence, nausea | |||
*Headache | |||
*Anemia | |||
*Chest pain | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 20-40min | ||
*Metabolism: | *Metabolism: Hepatic | ||
*Excretion: | *Excretion: | ||
*Mechanism of Action: | *Mechanism of Action: Synthetic prostaglandin E analogue | ||
==Comments== | ==Comments== | ||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Misoprostol]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
==See Also== | ==See Also== | ||
| Línea 43: | Línea 66: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] [[Category:OBGYN]] | ||
Revisión actual - 21:57 20 mar 2026
General
- Type: Prostaglandin
- Dosage Forms:
- Routes of Administration:
- Common Trade Names: Cytotec
Adult Dosing
Postpartum hemorrhage
- Second Line therapy and can be administered sublingually, orally, vaginally, and rectally.[1]
- 1,000 mcg administered rectally
- 800 mcg PO
Pediatric Dosing
Special Populations
- Pregnancy Rating: X
- Lactation risk: Excreted in breastmilk
- Renal Dosing: not defined
- Hepatic Dosing: not defined
Contraindications
- Allergy to class/drug
- Pregnancy (when used to treat ulcers)
Adverse Reactions
Serious
- Anaphylaxis
- Dysrhythmia, MI
- GI bleed
- Uterine rupture
- Thromboembolic disorder
Common
- Diarrhea, abdominal pain, flatulence, nausea
- Headache
- Anemia
- Chest pain
Pharmacology
- Half-life: 20-40min
- Metabolism: Hepatic
- Excretion:
- Mechanism of Action: Synthetic prostaglandin E analogue
Comments
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| First trimester abortion | 800mcg vaginally, repeat once in 7 days if no response | Medical management of early pregnancy loss (<12 weeks) | Vaginal | Adult |
| Postpartum hemorrhage | 600 mcg SL or 1000 mcg PR | 2nd line uterotonic | SL/PR | Adult |
See Also
References
- ↑ Mousa HA, Alfirevic Z. Treatment for primary postpartum haemorrhage. Cochrane Database Syst Rev. 2003;(1):CD003249.